IMMERVISION
23.11.2021 20:38:09 CET | Business Wire | Press release
Immervision, the world’s leading developer of advanced vision systems combining optics, image processing, and sensor fusion technology, today announced its ultra-wide lenses will be integrated into IONODES’ PERCEPT body camera. This collaboration will give businesses and the general public greater peace of mind, by providing physical security workers with a body camera that can effectively capture in real-time any potential security threats or issues in high resolution and never miss a detail through a Panomorph lens with 180° field of view.
“In the physical security industry, the challenge that most companies face with body worn cameras is that the video fails to effectively capture what’s occurring due to narrow field-of-view and poor image resolution,” said Eric Tasso, President at IONODES. “By selecting Immervision technology and their team of experts, we are providing security, industrial and commercial organizations with the highest-quality wearable cameras to improve safety, enhance security, optimize business processes and provide transparency."
IONODES’ body-worn IoT device is the first of a series of products that combines Immervision’s ultra-wide-angle lens, image processing and sensor technology with IONODES 4K camera, and connects to Wi-Fi, Bluetooth and LTE. IONODES’ device integrates seamlessly with a GPS receiver and 9-axis motion sensor, allowing users to closely follow the field of view in real-time, to stabilize the image and provide location tracking to users, whether for security, prevention, monitoring or entertainment applications
“Over the last 20 years, Immervision has focused on cultivating and perfecting its expertise in advanced vision systems, giving devices in industries such as physical security the ability to truly perceive the world around them,” said Pascale Nini, President and CEO at Immervision. “Immervision and IONODES are deeply committed to offering the best vision systems in the market for security and surveillance, and we look forward to continuing to make more innovative strides in developing high-quality wearable camera devices and AI-based vision systems.”
About Immervision
With over 20 years of innovation, Immervision creates solutions to see beyond human vision. To enable a machine to exceed human vision and unlock the full potential of AI, we develop advanced vision systems combining optics, image processing, and sensor fusion technology. Our Deep Seeing Technology enables hardware and software manufacturers to equip smart devices with the best vision possible for any industry including transportation, security, defense, computing, robotics, and more. www.immervision.com
About IONODES
IONODES is focused on pushing the boundaries of video technology, developing the latest in IP video storage, management and display solutions. Its experience in IP video and strong partnerships with industry leaders deliver innovative products designed to enhance people’s lifestyle while ensuring their safety and security.
IONODES designs, develops, and manufactures IP-based video solutions optimized for use in video surveillance. Its products include smart IP video appliances, such as body worn cameras, video encoders, video wall appliances, recording servers and workstations. The company offers its products through distributors, resellers, and representatives worldwide.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211123006095/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin6.8.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today it is working with the U.S. Department of Verterans Affairs (VA) on a multi-site randomized controlled clinical trial. The study will evaluate the safety and efficacy of COMP360 psilocybin in the treatment of treatment-resistant depression (TRD) in veterans, including those with concurrent post-traumatic stress disorder (PTSD). The trial, titled "Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression," or PIVOT, reflects VA’s commitment to pursuing innovative solutions for veterans who have not responded to existing treatments. Compass will donate the study drug - COMP360, a synthetic, proprietary pharmaceutical-grade formulation of psilocybin optimized for stability and purity. Compass will support the education and training of the investigators and their training team through the provision of training
Great Britain Leads Europe’s FMCG Inflation as NIQ Launches New Inflation Barometer6.8.2026 09:00:00 CEST | Press release
NIQ (NYSE: NIQ) today launches its new EU5 FMCG Inflation Barometer - a monthly tracker across five Western Europe markets – France, Great Britain, Germany, Italy and Spain – designed to help retailers, manufacturers and the media understand how inflation is evolving across Europe’s largest grocery markets and how shoppers are responding. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806579111/en/ EU5 CPG Inflation slows to +1.1% The first edition of the Barometer reveals that while inflation across Europe’s FMCG sector remains relatively contained overall, significant differences persist between countries. Key findings include: Great Britain recorded the highest FMCG inflation across the EU5 at +2.3%1, above the European average of +1.1%. France and Italy reported the lowest inflation at -0.4% and +0.6% retrospectively, highlighting the uneven inflationary landscape across Europe's major economies. The monthly Barometer
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN® APN6.8.2026 06:30:00 CEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom